LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells

Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation

(2010) Jolie Kiemlian Kwee et al.   ANTI-CANCER DRUGS

New pterocarpanquinones: Synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-α modulation in human PBMC cells

(2010) Chaquip D. Netto et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

(2009) F. Castagnetti et al.   BLOOD

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD

Imatinib resistance in CML

(2008) Gisella Volpe et al.   CANCER LETTERS

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

(2008) David L. DeRemer et al.   CLINICAL THERAPEUTICS

(±)-3,4-Dihydroxy-8,9-methylenedioxypterocarpan and derivatives: Cytotoxic effect on human leukemia cell lines

(2008) Chaquip D. Netto et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY